Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO)

Scandinavian Journal of Rheumatology

Volumn 34, Issue 1, 2005, Pages 40-44

  Hetland, Merete Lund ^a,b   Unkerskov, J ^c   Ravn, T ^c   Friis, M ^c   Tarp, U ^d   Andersen, L S ^e,f   Petri, A ^a,b   Khan, H ^a,b   Stenver, D I ^c   Hansen, A ^a,b   Ostergaard M ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c DANISH MEDICINES AGENCY   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e King Christian the Xth Hospital   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ADULT; AGE; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; BIOLOGICAL THERAPY; CANCER; DATA BASE; DENMARK; DIARRHEA; DISEASE DURATION; DRUG SURVEILLANCE PROGRAM; ECZEMA; EPISCLERITIS; ERYSIPELAS; FEMALE; FEVER; FRACTURE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INFECTION; INTESTINE INFECTION; LIVER TOXICITY; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; PROSTHESIS INFECTION; RHEUMATOID ARTHRITIS; RISK FACTOR; STATISTICS; THORAX PAIN;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; BIOLOGICAL THERAPY; DATABASES, FACTUAL; DENMARK; FEMALE; HUMANS; HYPERSENSITIVITY; INFECTION; MALE; MIDDLE AGED; REGISTRIES; RHEUMATOLOGY;

EID: 20144389095     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740510017968     Document Type: Article

References (15)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
5. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
6. Skapenko A, Kalden JR, Schulze-Koops H. Treatment of rheumatoid arthritis in the third millennium. Scand J Rheumatol 2001;30:249-54.
7. Forre O, Haugen M, Hassfeld WG. New treatment possibilities in rheumatoid arthritis. Scand J Rheumatol 2000; 29:73-84.
8. Kvien TK, Mikkelsen K, Nordvag BY. Results from controlled clinical trials: how relevant for clinical practice? J Rheumatol 2003;30:1135-7.
9. R Development Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2003.
10. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
11. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl 2:ii30-3.
12. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
13. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002;29:667-77.
14. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
15. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21.